Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory blood-based biomarkers to aid in the assessment and prognostication of traumatic brain injury: a TRACK-TBI study.

Journal of neuroinflammation·2026
Same author

The performance of a novel, diabetes-specific cognitive screening tool against the MoCA in older adults with type 2 diabetes.

BMC geriatrics·2026
Same author

Lipodystrophy: an uncommon cause of insulin resistance and young-onset diabetes.

JCEM case reports·2026
Same author

Plasma Biomarkers of Brain Injury in Critically Ill Children Receiving Extracorporeal Membrane Oxygenation.

JAMA pediatrics·2026
Same author

Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related Dementias.

Neurology·2026
Same author

The oxygen sensitivity of [4Fe-4S] clusters on the nitrogenase scaffold protein NifU.

Journal of inorganic biochemistry·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Catherine Demos1, Jermaine Brown1, Brian Ngo1

  • 1Meso Scale Diagnostics, LLC., Rockville, MD, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

This study identified key cerebrospinal fluid (CSF) biomarkers, including pTau217, that predict Alzheimer

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Alzheimer's Disease Research

Background:

  • Alzheimer's disease (AD) is a complex neurodegenerative disorder with a long preclinical phase.
  • Monitoring pathological changes like neurodegeneration and inflammation may enable early intervention.
  • Multi-biomarker assessment can guide personalized therapeutic strategies.

Purpose of the Study:

  • To identify cerebrospinal fluid (CSF) biomarkers for predicting dementia progression.
  • To explore biomarkers associated with neurodegeneration, inflammation, and metabolic stress in cognitive decline.
  • To assess the utility of biomarkers in differentiating individuals at risk of progressing to dementia.

Main Methods:

  • Measured 54 CSF biomarkers in individuals with AD dementia, MCI progressors, MCI non-progressors, and SCD using MULTI-ARRAY technology.
  • Selected biomarkers targeting neurovascular dysfunction, inflammation, neurodegeneration, tissue injury, and metabolic stress.
  • Utilized ANOVA and ROC curve analysis (AUC) to determine group differences and predictive utility.

Main Results:

  • 30 CSF biomarkers showed significant concentration differences across cognitive groups.
  • 17 analytes differed significantly between MCI progressors and non-progressors.
  • Ten proteins, notably pTau217 (AUC > 0.99), demonstrated high accuracy in predicting MCI progression to dementia.

Conclusions:

  • Identified novel CSF biomarkers indicative of dementia or progression to dementia, reflecting diverse pathological mechanisms.
  • These biomarkers show potential for personalized treatment and stratification in clinical trials.
  • Further integration into panels may enhance understanding of early AD pathology and progression.